Part II

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Tranxene Capsules 7.5 mg

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each capsule contains dipotassium clorazepate 7.5 mg.

For excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Capsule, hard
Maroon/grey hard gelatin capsule imprinted with the product name, 7.5 mg and the company symbol.

4 CLINICAL PARTICULARS

4.1 Therapeutic Indications

Anxiety:
Benzodiazepines are only indicated when the disorder is severe, disabling or subjecting the individual to extreme distress.

4.2 Posology and method of administration

Anxiety:

Treatment should be as short as possible (2-4 weeks). The patient should be reassessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free.

Treatment should be started with the lowest recommended dose. The maximum dose should not be exceeded.

Adults
One capsule (7.5 mg) up to 3 times daily.

Children
Not generally recommended for children under 16 years.

Elderly
Half the normal dose may be sufficient for a therapeutic response in the elderly.

The lowest dose which can control symptoms should be used, it should not be continued beyond 4 weeks.

Long term chronic use is not recommended.

Treatment should always be tapered off gradually.

Patients who have taken benzodiazepines for a long time may require a longer period during which doses are reduced.

4.3 Contraindications

Myasthenia gravis.
Hypersensitivity to benzodiazepines.
Severe respiratory insufficiency.
Sleep apnoea syndrome.
Severe hepatic insufficiency.

4.4 Special warnings and precautions for use

Tolerance

Some loss of efficacy to the hypnotic effects of benzodiazepines may develop after repeated use for a few weeks.

Dependence

Use of benzodiazepines may lead to the development of physical and psychic dependence upon these products. The risk of dependence increases with dose and duration of treatment; it is also greater in patients with a history of alcohol or drug abuse.

Once physical dependence has developed, abrupt termination of treatment will be accompanied by withdrawal symptoms. These may consist of headaches, muscle pain, extreme anxiety, tension, restlessness, confusion and irritability. In severe cases the following symptoms may occur: derealisation, depersonalisation, hyperacusis, numbness and tingling of the extremities, hypersensitivity to light, noise and physical contact, hallucinations or epileptic seizures.

Rebound insomnia and anxiety: a transient syndrome whereby the symptoms that led to treatment with a benzodiazepine recur in an enhanced form may occur on withdrawal of treatment. It may be accompanied by other reactions including mood changes, anxiety or sleep disturbances and restlessness. Since the risk of withdrawal phenomena/rebound phenomena is greater after abrupt discontinuation of treatment, it is recommended that the dosage is decreased gradually.

Duration of treatment
The duration of treatment should be as short as possible (see Posology) depending on the indication, but should not exceed 4 weeks. Extension beyond these periods should not take place without re-evaluation of the situation.

It may be useful to inform the patient when treatment is started that it will be of limited duration and to explain precisely how the dosage will be progressively decreased. Moreover it is important that the patient should be aware of the possibility of rebound phenomena, thereby minimising anxiety over such symptoms should they occur while the medicinal product is being discontinued.

There are indications that, in the case of benzodiazepines with a short duration of action, withdrawal phenomena can become manifest within the dosage interval, especially when the dosage is high. When benzodiazepines with a long duration of action are being used it is important to warn against changing to a benzodiazepine with a short duration of action, as withdrawal symptoms may develop.

Amnesia
Benzodiazepines may induce anterograde amnesia. The condition occurs most often several hours after ingesting the product and therefore to reduce the risk patients should ensure that they will be able to have an uninterrupted sleep of 7 - 8 hours (see also Undesirable Effects).

Psychiatric and 'paradoxical' reactions

Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, inappropriate behaviour and other adverse behavioural effects are known to occur when using benzodiazepines. Should this occur, use of the drug should be discontinued.

They are more likely to occur in children and the elderly.

Specific patient groups

Benzodiazepines should not be given to children without careful assessment of the need to do so; the duration of treatment must be kept to a minimum.

Elderly should be given a reduced dose (see Posology).

Because of the myorelaxant effect, there is a danger of falls and consequently of hip fractures, particularly for elderly patients.

A lower dose is also recommended for patients with chronic respiratory insufficiency due to the risk of respiratory depression. Benzodiazepines are not indicated to treat patients with severe hepatic insufficiency as they may precipitate encephalopathy.

Benzodiazepines are not recommended for the primary treatment of psychotic illness.

Benzodiazepines should not be used alone to treat depression or anxiety associated with depression (suicide may be precipitated in such patients).

Benzodiazepines should be used with extreme caution in patients with a history of alcohol or drug abuse.

4.5 Interaction with other medicinal products and other forms of interaction

Not recommended: Concomitant intake with alcohol

The sedative effect may be enhanced when the product is used in combination with alcohol. This affects the ability to drive or use machines.

Take into account: Combination with CNS depressants

Enhancement of the central depressive effect may occur in cases of concomitant use with antipsychotics (neuroleptics), hypnotics, anxiolytics/sedatives, antidepressant agents, narcotic analgesics, anti-epileptic drugs, anaesthetics and sedative antihistamines.

In the case of narcotic analgesics enhancement of the euphoria may also occur leading to an increase in psychic dependence.

Compounds which inhibit certain hepatic enzymes (particularly cytochrome P450) may enhance the activity of benzodiazepines. To a lesser degree this also applies to benzodiazepines that are metabolised only by conjugation.

4.6 Pregnancy and lactation

Benzodiazepines should only be used during pregnancy or lactation if considered essential by the physician. Animal studies with benzodiazepines have shown minor effects on the foetus while a few studies have reported late behavioural disturbance in offspring exposed *in utero*.

If the product is prescribed to a woman of child bearing potential, she should be warned to contact her physician regarding discontinuance of the product if she intends to become or suspects she is pregnant. If, for compelling medical reasons, the product is administered during the late phase of pregnancy, or during labour at high doses, effects on the neonate such as hypothermia, hypotonia and moderate respiratory depression, can be expected, due to the pharmacological action of the compound.

Moreover, infants born to mothers who took benzodiazepines chronically during the latter stages of pregnancy may have developed physical dependence and may be at some risk for developing withdrawal symptoms in the postnatal

period.

4.7 Effects on ability to drive and use machines

Sedation, amnesia, impaired concentration and impaired muscular function may adversely affect the ability to drive or to use machines. If insufficient sleep duration occurs, the likelihood of impaired alertness may be increased (see also Interactions).

4.8 Undesirable effects

Drowsiness, numbed emotions, reduced alertness, confusion, fatigue, headache, dizziness, muscle weakness, ataxia or double vision. These phenomena occur predominantly at the start of therapy and usually disappear with repeated administration.

Other side effects like gastrointestinal disturbances, changes in libido or skin reactions have been reported occasionally.

Amnesia

Anterograde amnesia may occur using therapeutic dosages, the risk increasing at higher dosages. Amnesic effects may be associated with inappropriate behaviour. (see Warnings and precautions).

Depression

Pre-existing depression may be unmasked during benzodiazepine use.

Psychiatric and 'paradoxical' reactions

Reactions like restlessness, agitation, irritability, aggressiveness, delusion, rages, nightmares, hallucinations, psychoses, inappropriate behaviour and other adverse behavioural effects are known to occur when using benzodiazepines or benzodiazepine-like agents. They may be quite severe with this product. They are more likely to occur in children and the elderly.

Dependence

Use (even at therapeutic doses) may lead to the development of physical dependence: discontinuation of the therapy may result in withdrawal or rebound phenomena (see Warnings and Precautions). Psychic dependence may occur. Abuse of benzodiazepines has been reported.

4.9 Overdose

As with other benzodiazepines, overdose should not present a threat to life unless combined with other CNS depressants (including alcohol).

In the management of overdose with any medical product, it should be borne in mind that multiple agents have been taken.

Following overdose with any medicinal product, vomiting should be induced (within one hour) if the patient is conscious or gastric lavage undertaken with the airway protected if the patient is unconscious. If there is no advantage in emptying the stomach, activated charcoal should be given to reduce absorption. Special attention should be paid to respiratory and cardiovascular functions in intensive care.

Overdose of benzodiazepines usually manifested by degrees of central nervous system depression ranging from drowsiness to coma. In mild cases, symptoms include drowsiness, mental confusion and lethargy, in more serious cases, symptoms may include ataxia, hypotonia, hypotension, respiratory depression, rarely coma and very rarely death.

Flumazenil may be useful as an antidote.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Tranxene is a tranquilliser exhibiting many characteristics of the benzodiazepine group of preparations. Particular features which distinguish Tranxene from other members of this group are the rapid appearance in the blood of the anxiolytic compound, nordiazepam, the maintenance of satisfactory therapeutic effect in most patients with once daily administration and little sedation. In common with other benzodiazepines, Tranxene has a central muscle relaxant effect and synergism with peripherally acting muscle relaxants is a theoretical possibility.

5.2 Pharmacokinetic properties

After oral administration of Tranxene, there is essentially no circulating parent drug. Nordiazepam, its primary metabolite, quickly appears in the blood stream. The serum half life is about 2 days. Tranxene is metabolised in the liver. In 2 volunteers given 15 mg (50 *micro*C) of ^{14}C-Tranxene, about 80% was recovered in the urine and faeces within 10 days. Excretion was primarily in the urine with about 1% excreted per day on day 10.

5.3 Preclinical safety data

None stated.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Ingredients:

Potassium Carbonate
Talc

Capsule Shell Ingredients:

Erythrosine	(E 127)
Indigo Carmine	(E 132)
Iron Oxide black	(E 172)
Iron Oxide red	(E 172)
Titanium Dioxide	(E 171)
Gelatin	

6.2 Incompatibilities

Not applicable.

6.3 Shelf Life

5 years.

6.4 Special precautions for storage

Do not store above 25°C.

Store in the original package.

6.5 Nature and contents of container

Registered packs: (1) Aluminium foil strips.
(2) Tropical blister packs.

Registered pack sizes: 20, 28 & 100.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

None stated.

7 MARKETING AUTHORISATION HOLDER

Boehringer Ingelheim Limited
Ellesfield Avenue
Bracknell
Berkshire, RG12 8YS
United Kingdom

8 MARKETING AUTHORISATION NUMBER

PA 7/4/3

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 15 March 1984

Date of last renewal: 15 March 2004

10 DATE OF REVISION OF THE TEXT

November 2005